Stable Imidazo[4,5-b]Pyridine Compounds Modulating AURKA–TPX2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments targeting Aurora Kinase A (AURKA) and its interacting protein TPX2 face challenges due to limited therapeutic index, metabolic instability, and potential harmful side-effects, necessitating the development of metabolically stable compounds that modulate AURKA conformation to selectively target diseased cells.
Innovation Solution
Development of nine-membered heterocyclic compounds, such as imidazo[4,5-b]pyridine derivatives, that interact with AURKA to modulate its binding to TPX2, thereby enhancing therapeutic efficacy while minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional AURKA inhibitors are used to target cancer cells, then therapeutic effectiveness is improved, but metabolic stability deteriorates leading to limited therapeutic index
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of AURKA inhibitors through various substitutions and modifications to improve metabolic stability while maintaining therapeutic effectiveness. Specific structural parameters such as molecular weight, lipophilicity, and metabolic stability parameters are optimized through systematic chemical modifications.
Solution Approach 2:
The patent employs composite materials by combining different chemical moieties and structural elements to create hybrid inhibitor molecules that exhibit both high therapeutic effectiveness and improved metabolic stability. The composite structures integrate multiple functional groups that work synergistically to achieve the desired therapeutic index.
2Reliability
If AURKA binding compounds are developed to modulate TPX2 interaction, then therapeutic index is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex AURKA-TPX2 interaction interface into distinct binding regions and targeting specific segments with modular compound designs. This allows for simplified compound structures that selectively target key interaction sites rather than requiring complex molecules to engage the entire interface.
Solution Approach 2:
The patent uses intermediary principles by introducing small molecule compounds that act as mediators between AURKA and TPX2, modulating their interaction without requiring direct complex binding to both proteins simultaneously. These intermediary compounds simplify the therapeutic approach while maintaining high therapeutic index.
3Productivity
If current cancer therapies are administered to achieve tumor remission, then cancer cell proliferation is inhibited, but toxicity increases necessitating restricted dosing
Solution Approach 1:
The patent applies the blessing in disguise principle by converting the normally harmful off-target effects and toxicity into selective therapeutic benefits through optimized compound design. The modified compounds exhibit enhanced selectivity for cancer cell targets while minimizing off-target toxicity, effectively converting potential harmful interactions into beneficial selective action.
Solution Approach 2:
The patent employs dynamics by designing compounds with dynamic properties that allow selective activation in cancer cells versus normal cells. The compounds may exhibit conditional activation, metabolic stability differences, or target engagement dynamics that are favorable in the cancer cell context, enabling higher effective doses with reduced toxicity.
Data Source
Figure 1A~1E
Figure 2A~2E
Figure 3A~3D
AI summary
The present invention relates to metabolically stable compounds that modulate the binding of AURKA to its interacting proteins, especially TPX2. The compounds of the present invention have high therapeutic efficiency due to its high metabolic stability and low toxicity. The present invention also pertains to the use of such compounds in the prevention and/or treatment of proliferative diseases, such as cancer, and kits comprising the same.